Company expands leadership team with focus on reimbursement for artificial intelligence clinical in vitro diagnostic, KidneyIntelX™ NEW YORK, July 29, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces the
Data development plan review continues with FDA under Breakthrough Device designation process; Performance meets or exceeds targets for identifying rapid kidney function decline in patients with Type 2 diabetes and existing chronic kidney disease NEW YORK, July 9, 2019 /PRNewswire/ -- Renalytix AI
CPT Code a key component for reimbursement from private medical insurance and Medicare NEW YORK, July 1, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the American Medical
Positive study results support successful development of a predictive blood test for transplant patients to meet critical unmet medical need NEW YORK, June 7, 2019 /PRNewswire/ -- Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease,
Investigators now include transplant experts from University of Oxford, Yale School of Medicine, Emory University School of Medicine, Icahn School of Medicine at Mount Sinai, University of Manitoba, Westmead Hospital Sydney, University of Alabama at Birmingham, and Cleveland Clinic NEW YORK, May
NEW YORK, May 7, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today a collaboration with University Medical Center Groningen (UMCG), Netherlands, to evaluate KidneyIntelX™ across over 3,500
Provides Priority Regulatory Review of AI-Enabled Diagnostic for Fast-Progressing Kidney Disease NEW YORK, May 2, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that it has been granted
Investigators include leading transplant clinicians from Emory University, the University of Manitoba, the Westmead Hospital Sydney, and Icahn School of Medicine at Mount Sinai NEW YORK, March 22, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled
NEW YORK, Feb. 13, 2019 /PRNewswire/ -- RenalytixAI (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, today announced the completion of a joint venture partnership agreement with AKESOgen, an industry-leading commercial laboratory facility and provider of
Company Adds Clinical and Data Security Expertise to Support KidneyIntelX Clinical Validation, Software and Regulatory Programs NEW YORK, Feb. 6, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, today announced the
